Sophia DDM Platform

Search documents
Strategic Partnerships Power Tempus AI's Healthcare Expansion
ZACKSยท 2025-08-19 14:36
Core Insights - Tempus AI, Inc. (TEM) is rapidly expanding its partnerships in oncology and neuroscience, utilizing its AI platforms, Lens and Next, to enhance precision medicine [1] Partnerships and Collaborations - Tempus has initiated a multi-year collaboration with The Abrams Research Center at Northwestern University to utilize its AI-powered Lens platform for genomic data analysis in Alzheimer's research [2] - In February, Tempus partnered with the Institute for Follicular Lymphoma Innovation to create a deidentified data library in Lens, aimed at accelerating treatment development for follicular lymphoma [2] - In May, Tempus formed a strategic collaboration with Boehringer Ingelheim to advance cancer pipeline research, building on previous joint efforts [3] - Earlier this year, Tempus and Stemline Therapeutics announced a collaboration to enhance oncology treatments using the AI-enabled Next platform [3] - In January, Tempus partnered with Genialis to leverage its multimodal dataset for developing new RNA-based algorithms across various cancer types [4] Industry Comparisons - Sophia Genetics expanded its partnership with AstraZeneca to utilize its AI Factories for breast cancer therapy research, while also collaborating with Result Laboratorium for pharmacogenomics insights [5] - AbbVie announced collaborations with ADARx Pharmaceuticals and Gubra A/S to develop therapeutics across multiple disease areas, including oncology [6] Stock Performance - Over the past year, Tempus AI shares have increased by 35.9%, outperforming the industry growth of 21.4% and the S&P 500's 15.9% improvement [7] Valuation Metrics - Tempus currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 9.38, significantly higher than the industry average of 5.87 [10] Earnings Estimates - Recent estimates for Tempus AI's loss per share have shown mixed movements for 2025 and 2026, with current estimates at -0.16 for Q3 2025 and -0.70 for the current year [11][12]